Scarica l'app Stockscreener
6.10
1.21%
-0.075
Dopo l'orario di chiusura:
6.16
0.06
+0.98%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Pharmaceuticals CEO sells $301,800 in stock - Investing.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.9% Following Insider Selling - MarketBeat
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Trims Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals CFO Michael Secora sells $229,504 in stock - Investing.com
Recursion Pharmaceuticals director Blake Borgeson sells $87,457 in stock - Investing.com
Pier 88 Investment Partners LLC Acquires 109,210 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition - Investing.com
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition By Investing.com - Investing.com UK
Recursion, Exscientia shareholders back merger - Investing.com
Recursion and Exscientia Shareholders Approve the Proposed Combination - The Manila Times
Recursion & Exscientia Merger Approved: AI Drug Discovery Giants Set to Unite | RXRX Stock News - StockTitan
Recursion releases OpenPhenom-S/16 for microscopy data By Investing.com - Investing.com Australia
FMR LLC's Strategic Acquisition in Recursion Pharmaceuticals Inc - GuruFocus.com
Recursion releases OpenPhenom-S/16 for microscopy data - Investing.com
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden - GlobeNewswire
Recursion Pharmaceuticals, Inc. Announces the Release of OpenPhenom-S/16 in Google Cloud?s Model Garden - Marketscreener.com
Baillie Gifford & Co. Cuts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for RXRX Earnings - MarketBeat
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - Simply Wall St
Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - Yahoo Finance
ARK Investment Management LLC Boosts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk - Simply Wall St
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals - Benzinga
Recursion Pharmaceuticals' (RXRX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Recursion Pharmaceuticals Reports Q3 2024 Earnings and Strategic Milestones - TipRanks
Recursion Pharmaceuticals: Q3 Earnings Snapshot - Barchart
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Recursion Pharmaceuticals Inc Cl A (RXRX-Q) QuotePress Release - The Globe and Mail
Is Recursion Pharmaceuticals a Millionaire-Maker Stock? - AOL
Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Pre - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition in Recursion Pharmace - GuruFocus.com
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider - MSN
(RXRX) Technical Pivots with Risk Controls - Stock Traders Daily
Could This Near Trillion-Dollar Stock Be a Millionaire Maker? - AOL
Mirae Asset Global Investments Co. Ltd. Purchases 80,664 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals director Blake Borgeson sells $76,926 in stock - Investing.com India
Recursion Pharmaceuticals director Blake Borgeson sells $76,926 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals (RXRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th - StockTitan
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.6% After Insider Selling - MarketBeat
Recursion Pharmaceuticals president Tina Marriott sells $37,854 in stock By Investing.com - Investing.com Canada
Recursion Pharmaceuticals president Tina Marriott sells $37,854 in stock - Investing.com
Tina Marriott Sells 6,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock - MarketBeat
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):